Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals (CRVS) is a clinical-stage biopharmaceutical company advancing novel immunotherapies targeting T cell modulation through ITK inhibition. This page provides investors and industry stakeholders with timely updates on CRVS’s clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases, earnings reports, and research updates in one centralized location. Track progress across the company’s pipeline, including soquelitinib for T cell lymphomas and autoimmune conditions, as well as collaborations shaping its therapeutic platform.
Key updates include clinical trial results, partnership announcements, and financial performance. Bookmark this page to stay informed about CRVS’s advancements in immuno-oncology and immune-mediated disease research. Visit regularly for authoritative insights into the company’s scientific and operational progress.
Corvus Pharmaceuticals (CRVS) has reported its Q4 and full year 2024 financial results, highlighting progress in its clinical programs. The company's lead drug soquelitinib showed promising interim results in atopic dermatitis trials, with 26% of patients achieving IGA 0/1 and 37% achieving EASI 75 in the first two cohorts, compared to zero in the placebo group.
The company is advancing multiple clinical trials, including a Phase 3 registration trial for peripheral T cell lymphoma (PTCL) and a new Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS). Financial results show cash position of $52.0 million as of December 31, 2024, up from $27.1 million in 2023. R&D expenses increased to $19.4 million for full year 2024, compared to $16.5 million in 2023. The company reported a Q4 net loss of $12.1 million.
Through a registered direct offering and warrant exercises, Corvus raised approximately $48.9 million in 2024. The company expects current cash to fund operations into Q1 2026.
Corvus Pharmaceuticals (NASDAQ: CRVS) has presented additional data from its Phase 1/1b clinical trial of soquelitinib for T cell lymphoma (TCL) treatment at the 16th Annual T-Cell Lymphoma Forum. The trial showed promising results with:
- 39% objective response rate (9 out of 23 evaluable patients)
- 26% complete response rate (6 patients)
- 17.2 months median duration of response
- 6.2 months median progression-free survival
- 30% progression-free survival rate at 18 months
The company is currently conducting a registrational Phase 3 trial enrolling 150 patients with relapsed Peripheral T cell lymphoma, comparing soquelitinib to belinostat or pralatrexate. Soquelitinib has received FDA Orphan Drug Designation for T cell lymphoma and Fast Track designation for relapsed/refractory PTCL treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The clinical-stage biopharmaceutical company's leadership team will engage in one-on-one meetings with investors and participate in a fireside chat presentation scheduled for March 27, 2025, at 12:00 pm ET.
The virtual presentation will be accessible through a webcast that will remain available for 90 days after the event via the company's investor relations website section.
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has scheduled its fourth quarter and full year 2024 financial results announcement for March 25, 2025. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT.
Investors can access the conference call through toll-free domestic (1-800-717-1738) or international (1-646-307-1865) numbers. A webcast will be available through the investor relations section of Corvus' website, with replay access for 90 days following the event.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced the initiation of a Phase 2 clinical trial of soquelitinib for treating Autoimmune Lymphoproliferative Syndrome (ALPS), a rare genetic disease. The trial will be conducted by NIH/NIAID in partnership with Corvus.
The study will enroll up to 30 patients aged 16 or older with confirmed ALPS-FAS, testing two dosing cohorts of 200mg and 400mg twice daily for up to 360 days. The primary endpoint focuses on reducing splenomegaly and lymph node volumes, with secondary endpoints including safety and tolerability.
This marks the third indication for soquelitinib, alongside its ongoing Phase 3 trial for peripheral T cell lymphoma (PTCL) and Phase 1 trial for atopic dermatitis. Corvus plans to initiate an additional Phase 1 trial for solid tumors in Q2 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event. The clinical-stage biopharmaceutical company's leadership team will deliver a corporate overview presentation on Tuesday, February 11, 2025, at 9:20 am ET.
The company will also conduct one-on-one meetings with investors during the conference. A webcast of the presentation will be accessible through the investor relations section of Corvus's website, with availability both live and for 90 days following the event.
Corvus Pharmaceuticals (NASDAQ: CRVS) has released new interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial, which includes data from 26 patients across two cohorts, showed promising results with 26% of treated patients achieving IGA 0 or 1 and 37% achieving EASI 75, while no placebo patients reached these endpoints.
The study evaluated two dosing regimens: Cohort 1 with 100 mg twice daily (12 patients) and Cohort 2 with 200 mg once daily (7 patients), against placebo groups. All Cohort 2 patients completed the 28-day treatment period with no significant safety issues or laboratory abnormalities. The trial is designed to enroll 64 patients total across four cohorts, with full results expected in Q2 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 13-16, 2025. Richard A. Miller, M.D., the company's president and chief executive officer, will engage in one-on-one investor meetings and deliver a corporate overview presentation.
The presentation is scheduled for Wednesday, January 15, 2025, at 2:15 pm ET / 11:15 am PT. An audio webcast will be available live and accessible for 30 days after the event through the investor relations section of Corvus's website.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial's lowest dose cohort demonstrated favorable safety and efficacy profiles. Key findings include:
- Mean EASI score reduction of 55.9% at 28 days and 69.1% at 58 days in the treatment group, compared to 27.0% and 19.1% in placebo
- Nine of 12 patients achieved EASI 50 at day 28, with three achieving EASI 75 and one reaching EASI 90
- No significant safety issues were observed during the trial
Additionally, Samlyn Capital exercised warrants to purchase 3,633,978 shares, providing approximately $12.7 million in cash proceeds to Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will release interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024. The trial is a randomized, double-blind, placebo-controlled study evaluating the drug in patients with moderate to severe atopic dermatitis. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to present the data, which will also be released via press release. The presentation will include slides and be accessible through a toll-free domestic line or international dial-in, with a webcast replay available on the company's website for 60 days.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
